GlassScriptPhysician profile
John Randolph Morgan
NPI 1487767224
$4,823.59
in general payments reported to CMS, 2019-2025
32 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $36.25 · 2021: $15.54 · 2022: $960 · 2023: $1,078 · 2024: $952 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,284.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $838.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $513.93 | 2022-2025 | |
| Amgen INC. | $491.12 | 2022-2025 | Repatha, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $412.57 | 2022-2025 | Rexulti |
| Abbott Laboratories | $391.66 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $387.92 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $361.30 | 2022-2025 | |
| Glaxosmithkline, LLC. | $253.91 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.53 | 2019-2025 | Jardiance |
| Dexcom, INC. | $141.18 | 2022-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $118.30 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $86.71 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Acadia Pharmaceuticals INC | $77.80 | 2019 | |
| Axsome Therapeutics, INC. | $74.02 | 2023-2025 | Sunosi, Auvelity |
| Pfizer INC. | $68.60 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.99 | 2023-2025 | Xifaxan |
| Scynexis, INC. | $57.21 | 2022 | |
| Xeris Pharmaceuticals, INC. | $41.61 | 2023 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $41.03 | 2024 | Inspire |
| Harmony Biosciences LLC | $33.96 | 2024 | |
| Seqirus USA INC | $23.67 | 2025 | Flucelvax |
| Teva Pharmaceuticals USA, INC. | $23.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.80 | 2025 | |
| Medtronic, INC. | $22.07 | 2024 | Intellis Adaptivestim |
| Dynavax Technologies Corporation | $21.14 | 2023 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $19.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.32 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.14 | 2023 | |
| Sanofi Pasteur INC. | $16.17 | 2024 | |
| Merck Sharp & Dohme LLC | $16.07 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Becton, Dickinson and Company | $15.54 | 2021 | |
| Currax Pharmaceuticals LLC | $14.73 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.